OncoSec Medical (FRA:ONMA) Long-Term Capital Lease Obligation : €0.20 Mil (As of Jan. 2023)

View and export this data going back to 2015. Start your Free Trial

What is OncoSec Medical Long-Term Capital Lease Obligation?

OncoSec Medical's Long-Term Capital Lease Obligation for the quarter that ended in Jan. 2023 was €0.20 Mil.

OncoSec Medical's quarterly Long-Term Capital Lease Obligation declined from Jul. 2022 (€4.06 Mil) to Oct. 2022 (€3.57 Mil) and declined from Oct. 2022 (€3.57 Mil) to Jan. 2023 (€0.20 Mil).

OncoSec Medical's annual Long-Term Capital Lease Obligation declined from Jul. 2020 (€5.11 Mil) to Jul. 2021 (€4.43 Mil) and declined from Jul. 2021 (€4.43 Mil) to Jul. 2022 (€4.06 Mil).

OncoSec Medical Long-Term Capital Lease Obligation Historical Data

The historical data trend for OncoSec Medical's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Long-Term Capital Lease Obligation Chart

OncoSec Medical Annual Data

Trend

Jul13

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

5.11

4.43

4.06

OncoSec Medical Quarterly Data
	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															4.16	4.09	4.06	3.57	0.20

OncoSec Medical (FRA:ONMA) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

OncoSec Medical Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoSec Medical (FRA:ONMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (FRA:ONMA) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ONCSQ:USA

Address

24 North Main Street, Pennington, NJ, USA, 08534

Website

https://www.oncosec.com

OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

OncoSec Medical (FRA:ONMA) Headlines

No Headlines